Professor Dan Huh of the University of Pennsylvania Introduces Organ-on-a-Chip Technology

Exploring Biotech Collaboration, from Organoids to AI-Based Drug Development

Technology that uses chips mimicking the functions of human organs to reduce animal testing and assess the safety and efficacy of new drugs is attracting attention.


Dan Huh, a professor at the University of Pennsylvania in the United States and an expert in organ-on-a-chip technology, visited Busan to discuss the technology's potential and pathways to commercialization.


The Busan-Jinhae Free Economic Zone Authority, headed by Park Seongho, said on November 18 that it had held the Advanced Biotech Global Symposium jointly with Prestige BioPharma IDC on November 16.


The symposium brought together advanced biotechnology, including organ-on-a-chip technology, organoids, and artificial intelligence (AI)-based drug development, and discussed ways for local medical and biotech institutions and companies to collaborate.

The Busan-Jinhae Free Economic Zone Authority is holding the “Advanced Biopharma Global Symposium” jointly with Prestige BioPharma IDC on the 16th.

The Busan-Jinhae Free Economic Zone Authority is holding the “Advanced Biopharma Global Symposium” jointly with Prestige BioPharma IDC on the 16th.

View original image

In his keynote address, Professor Huh introduced organ-on-a-chip technology, which replicates the functions of organs such as the human lungs and liver on microchips. He noted that physiological differences between animals and humans limit the ability of conventional animal testing to accurately predict how drugs will affect the human body. He explained that organ-on-a-chip technology could offer an alternative for more precise assessments of the safety and therapeutic effects of new drugs.


Efforts are also underway in the United States to establish regulatory frameworks for technologies that replace animal testing. The FDA Modernization Act 2.0, which includes alternatives to animal testing, was enacted in December 2022, and the U.S. Food and Drug Administration (FDA) announced a roadmap to reduce animal testing in April 2025.


The symposium also addressed standardizing testing methods for organ-on-a-chip technology and organoids, securing regulatory acceptance, and AI-based drug development. MEPsGEN CEO Kim Yongtae presented on the need for automated organ-on-a-chip platforms and standardized testing methods.


Professor Kim Jeonghyeon of Ajou University discussed U.S. FDA policies on advanced alternative testing methods and ways to gain regulatory acceptance for organoid technology. Pyo Jeonghun, group leader at Prestige BioPharma IDC, introduced AI-based antibody drug development and open innovation strategies.


The panel discussion included the speakers, Lee Gyeongryun, team leader at the Korea Research Institute of Bioscience and Biotechnology; Professor Heo Jin of the Pusan National University College of Medicine; and Kim Daegyeong, director at Hicelltech. They discussed joint testing and evaluation using the medical and biotech infrastructure in the southeastern region, establishing a multi-institutional validation network, and linking local technologies to commercialization.


Before the symposium, Professor Huh visited Pusan National University Yangsan Hospital with Yoo Hak-seon, director of its Biomedical Convergence Research Institute, and Yang Jeonghui, center director at the Gimhae Biohealth Industry Promotion Agency. They toured the research facilities and reviewed the region's medical and biotech research capabilities, while exploring opportunities for global collaboration.


Administrator Park Seongho said, "The advanced biotech industry is transforming drug development through the convergence of AI and biotechnology."



He added, "We will expand our network of experts at home and abroad and identify collaborative research, technology validation, and commercialization projects that leverage the medical and biotech infrastructure in the southeastern region."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing